Dr. Stephanie Jeske is a board-certified medical oncologist who lives in San Francisco, California. She graduated from the Indiana University School of Medicine and did her residency in internal medicine at the University of Texas Southwestern Medical School. She also did a fellowship in hematology/oncology at the New York Presbyterian Hospital. With nearly 20 years of experience, she currently practices at the St. Luke’s Medical Center. She has also contributed to two research publications.
Dr. Stephanie Jeske has contributed to 2 publications.
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa, S. T., Milowsky, M. I., Jeske, S., Mazumdar, M., Kung, S., Sung, M., Lehrer, D., Matulich, D., Selzer, J., Wright, J. J., Nanus, D. M.; Am J Clin Oncol. 2011 Oct.
Dr. Stephanie Jeske is a board-certified medical oncologist who lives in San Francisco, California. She graduated from the Indiana University School of Medicine and did her residency in internal medicine at the University of Texas Southwestern Medical School. She also did a fellowship in hematology/oncology at the New York Presbyterian Hospital. With nearly 20 years of experience, she currently practices at the St. Luke’s Medical Center. She has also contributed to two research publications.
Dr. Stephanie Jeske has contributed to 2 publications.
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa, S. T., Milowsky, M. I., Jeske, S., Mazumdar, M., Kung, S., Sung, M., Lehrer, D., Matulich, D., Selzer, J., Wright, J. J., Nanus, D. M.; Am J Clin Oncol. 2011 Oct.
Hospitals & Clinics
specialties & services
